Cancer DNA blood test trial halted before it began
NCT ID NCT06613516
First seen Jan 10, 2026 · Last updated May 10, 2026 · Updated 15 times
Summary
This study aimed to see if the drug capivasertib could clear cancer DNA from the blood of 20 women with ER-positive breast cancer who were already on hormone therapy. The goal was to prevent the cancer from coming back or spreading. However, the trial was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.